Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 279

1.

Isolated central nervous system progression on Crizotinib: an Achilles heel of non-small cell lung cancer with EML4-ALK translocation?

Chun SG, Choe KS, Iyengar P, Yordy JS, Timmerman RD.

Cancer Biol Ther. 2012 Dec;13(14):1376-83. doi: 10.4161/cbt.22255. Epub 2012 Sep 17.

PMID:
22986231
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.

Katayama R, Khan TM, Benes C, Lifshits E, Ebi H, Rivera VM, Shakespeare WC, Iafrate AJ, Engelman JA, Shaw AT.

Proc Natl Acad Sci U S A. 2011 May 3;108(18):7535-40. doi: 10.1073/pnas.1019559108. Epub 2011 Apr 18.

PMID:
21502504
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

The biology and clinical features of non-small cell lung cancers with EML4-ALK translocation.

Pillai RN, Ramalingam SS.

Curr Oncol Rep. 2012 Apr;14(2):105-10. doi: 10.1007/s11912-012-0213-4. Review.

PMID:
22311682
[PubMed - indexed for MEDLINE]
4.

ALK inhibitors in the treatment of advanced NSCLC.

Gridelli C, Peters S, Sgambato A, Casaluce F, Adjei AA, Ciardiello F.

Cancer Treat Rev. 2014 Mar;40(2):300-6. doi: 10.1016/j.ctrv.2013.07.002. Epub 2013 Aug 7. Review.

PMID:
23931927
[PubMed - indexed for MEDLINE]
5.

Long-lasting response to crizotinib in brain metastases due to EML4-ALK-rearranged non-small-cell lung cancer.

Kinoshita Y, Koga Y, Sakamoto A, Hidaka K.

BMJ Case Rep. 2013 Sep 10;2013. pii: bcr-2013-200867. doi: 10.1136/bcr-2013-200867.

PMID:
24022905
[PubMed - indexed for MEDLINE]
6.

Clinical impact of continued crizotinib administration after isolated central nervous system progression in patients with lung cancer positive for ALK rearrangement.

Takeda M, Okamoto I, Nakagawa K.

J Thorac Oncol. 2013 May;8(5):654-7. doi: 10.1097/JTO.0b013e31828c28e7.

PMID:
23584297
[PubMed - indexed for MEDLINE]
7.

ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC.

Casaluce F, Sgambato A, Maione P, Rossi A, Ferrara C, Napolitano A, Palazzolo G, Ciardiello F, Gridelli C.

Target Oncol. 2013 Mar;8(1):55-67. doi: 10.1007/s11523-012-0250-9. Epub 2013 Jan 17. Review.

PMID:
23325296
[PubMed - indexed for MEDLINE]
8.

ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.

Scagliotti G, Stahel RA, Rosell R, Thatcher N, Soria JC.

Eur J Cancer. 2012 May;48(7):961-73. doi: 10.1016/j.ejca.2012.02.001. Epub 2012 Mar 6.

PMID:
22397764
[PubMed - indexed for MEDLINE]
9.

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

Doebele RC, Pilling AB, Aisner DL, Kutateladze TG, Le AT, Weickhardt AJ, Kondo KL, Linderman DJ, Heasley LE, Franklin WA, Varella-Garcia M, Camidge DR.

Clin Cancer Res. 2012 Mar 1;18(5):1472-82. doi: 10.1158/1078-0432.CCR-11-2906. Epub 2012 Jan 10.

PMID:
22235099
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Identification and characterization of ALK kinase splicing isoforms in non-small-cell lung cancer.

de Figueiredo-Pontes LL, Wong DW, Tin VP, Chung LP, Yasuda H, Yamaguchi N, Nakayama S, Jänne PA, Wong MP, Kobayashi SS, Costa DB.

J Thorac Oncol. 2014 Feb;9(2):248-53. doi: 10.1097/JTO.0000000000000050.

PMID:
24419423
[PubMed - indexed for MEDLINE]
11.

Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer.

Yamaguchi N, Lucena-Araujo AR, Nakayama S, de Figueiredo-Pontes LL, Gonzalez DA, Yasuda H, Kobayashi S, Costa DB.

Lung Cancer. 2014 Jan;83(1):37-43. doi: 10.1016/j.lungcan.2013.09.019. Epub 2013 Oct 14.

PMID:
24199682
[PubMed - indexed for MEDLINE]
12.

Favorable response to crizotinib in three patients with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion-type oncogene-positive non-small cell lung cancer.

Kijima T, Takeuchi K, Tetsumoto S, Shimada K, Takahashi R, Hirata H, Nagatomo I, Hoshino S, Takeda Y, Kida H, Goya S, Tachibana I, Kawase I.

Cancer Sci. 2011 Aug;102(8):1602-4. doi: 10.1111/j.1349-7006.2011.01970.x.

PMID:
21767331
[PubMed - indexed for MEDLINE]
13.

Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.

O'Bryant CL, Wenger SD, Kim M, Thompson LA.

Ann Pharmacother. 2013 Feb;47(2):189-97. doi: 10.1345/aph.1R002. Epub 2013 Feb 5. Review.

PMID:
23386065
[PubMed - indexed for MEDLINE]
14.

Crizotinib in the treatment of non--small-cell lung cancer.

Rothschild SI, Gautschi O.

Clin Lung Cancer. 2013 Sep;14(5):473-80. doi: 10.1016/j.cllc.2013.04.006. Epub 2013 Jun 20. Review.

PMID:
23790969
[PubMed - indexed for MEDLINE]
15.

Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer.

Djalalov S, Beca J, Hoch JS, Krahn M, Tsao MS, Cutz JC, Leighl NB.

J Clin Oncol. 2014 Apr 1;32(10):1012-9. doi: 10.1200/JCO.2013.53.1186. Epub 2014 Feb 24.

PMID:
24567430
[PubMed - indexed for MEDLINE]
16.

Targeting anaplastic lymphoma kinase in lung cancer.

Shaw AT, Solomon B.

Clin Cancer Res. 2011 Apr 15;17(8):2081-6. doi: 10.1158/1078-0432.CCR-10-1591. Epub 2011 Feb 2. Review.

PMID:
21288922
[PubMed - indexed for MEDLINE]
Free Article
17.

New targets in advanced NSCLC: EML4-ALK.

Crystal AS, Shaw AT.

Clin Adv Hematol Oncol. 2011 Mar;9(3):207-14. Review.

PMID:
21475126
[PubMed - indexed for MEDLINE]
18.

Preselection based on clinical characteristics in German non-small-cell lung cancer patients screened for EML4-ALK translocation.

Tufman AL, Edelmann M, Gamarra F, Reu S, Borgmeier A, Schrödl K, Zauber R, Müller-Lisse U, Huber RM.

J Thorac Oncol. 2014 Jan;9(1):109-13. doi: 10.1097/JTO.0000000000000043.

PMID:
24346098
[PubMed - indexed for MEDLINE]
19.

Crizotinib in the treatment of non-small-cell lung cancer.

Forde PM, Rudin CM.

Expert Opin Pharmacother. 2012 Jun;13(8):1195-201. doi: 10.1517/14656566.2012.688029. Review.

PMID:
22594847
[PubMed - indexed for MEDLINE]
20.

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.

Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S, McDermott U, Settleman J, Kobayashi S, Mark EJ, Rodig SJ, Chirieac LR, Kwak EL, Lynch TJ, Iafrate AJ.

J Clin Oncol. 2009 Sep 10;27(26):4247-53. doi: 10.1200/JCO.2009.22.6993. Epub 2009 Aug 10.

PMID:
19667264
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk